Show simple item record

Exisulind and CP248 induce growth inhibition and apoptosis in human esophageal adenocarcinoma and squamous carcinoma cells

dc.contributor.authorJoe, Andrew K.en_US
dc.contributor.authorLiu, Huien_US
dc.contributor.authorXiao, Danhuaen_US
dc.contributor.authorSoh, Jae-Wonen_US
dc.contributor.authorPinto, John T.en_US
dc.contributor.authorBeer, David G.en_US
dc.contributor.authorPiazza, Gary A.en_US
dc.contributor.authorJoseph Thompson, W.en_US
dc.contributor.authorBernard Weinstein, I.en_US
dc.date.accessioned2010-06-01T22:28:47Z
dc.date.available2010-06-01T22:28:47Z
dc.date.issued2003-03en_US
dc.identifier.citationJoe, Andrew K.; Liu, Hui; Xiao, Danhua; Soh, Jae-Won; Pinto, John T.; Beer, David G.; Piazza, Gary A.; Joseph Thompson, W.; Bernard Weinstein, I. (2003). "Exisulind and CP248 induce growth inhibition and apoptosis in human esophageal adenocarcinoma and squamous carcinoma cells." Journal of Experimental Therapeutics and Oncology 3(2): 83-94. <http://hdl.handle.net/2027.42/75468>en_US
dc.identifier.issn1359-4117en_US
dc.identifier.issn1533-869Xen_US
dc.identifier.urihttps://hdl.handle.net/2027.42/75468
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=12822514&dopt=citationen_US
dc.format.extent2229495 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Science Incen_US
dc.rightsBlackwell Publishing Inc. 2003en_US
dc.subject.otherBarrett's Esophagusen_US
dc.subject.otherChemopreventionen_US
dc.subject.otherCP248en_US
dc.subject.otherExisulinden_US
dc.titleExisulind and CP248 induce growth inhibition and apoptosis in human esophageal adenocarcinoma and squamous carcinoma cellsen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumUniversity of Michigan, Ann Arbor, MI, anden_US
dc.contributor.affiliationotherHerbert Irving Comprehensive Cancer Center,en_US
dc.contributor.affiliationotherDepartment of Medicine, College of Physicians & Surgeons of Columbia University, New York, NYen_US
dc.contributor.affiliationotherAmerican Health Foundation, Valhalla, NY,en_US
dc.contributor.affiliationotherCell Pathways, Inc., Horsham, PA, U.S.A.en_US
dc.identifier.pmid12822514en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/75468/1/j.1359-4117.2003.01076.x.pdf
dc.identifier.doi10.1046/j.1359-4117.2003.01076.xen_US
dc.identifier.sourceJournal of Experimental Therapeutics and Oncologyen_US
dc.identifier.citedreferenceRiddell RH. Early detection of neoplasia of the esophagus and gastroesophageal junction. Am J Gastroenterol 91: 853 – 863, 1996.en_US
dc.identifier.citedreferenceRusch VW, Levine DS, Haggitt R, Reid BJ. The management of high grade dysplasia and early cancer in Barrett's esophagus. A multidisciplinary problem. Cancer 74: 1225 – 1229, 1994.en_US
dc.identifier.citedreferenceThun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325: 1593 – 1596, 1991.en_US
dc.identifier.citedreferenceGoldberg Y, Nassif II, Pittas A, Tsai LL, Dynlacht BD, Rigas B, Shiff SJ. The anti-proliferative effect of sulindac and sulindac sulfide on HT-29 colon cancer cells: alterations in tumor suppressor and cell cycle-regulatory proteins. Oncogene, 12: 893 – 901, 1996.en_US
dc.identifier.citedreferencePiazza GA, Alberts DS, Hixson LJ, et al. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res 57: 2909 – 2915, 1997.en_US
dc.identifier.citedreferenceLim JT, Piazza GA, Han EK, et al. Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines. Biochem Pharmacol 58: 1097 – 1107, 1999.en_US
dc.identifier.citedreferencePiazza GA, Rahm AL, Krutzsch M, et al. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res 55: 3110 – 3116, 1995.en_US
dc.identifier.citedreferenceThompson HJ, Jiang C, Lu J, Mehta RG, Piazza GA, Paranka NS, Pamukcu R, Ahnen DJ. Sulfone metabolite of sulindac inhibits mammary carcinogenesis. Cancer Res 57: 267 – 271, 1997.en_US
dc.identifier.citedreferenceHan EK, Arber N, Yamamoto H, et al. Effects of sulindac and its metabolites on growth and apoptosis in human mammary epithelial and breast carcinoma cell lines. Breast Cancer Res Treat 48: 195 – 203, 1998.en_US
dc.identifier.citedreferenceRahman MA, Dhar DK, Masunaga R, Yamanoi A, Kohno H, Nagasue N. Sulindac and exisulind exhibit a significant antiproliferative effect and induce apoptosis in human hepatocellular carcinoma cell lines. Cancer Res 60: 2085 – 2089, 2000.en_US
dc.identifier.citedreferenceThompson WJ, Piazza GA, Li H, et al. Exisulind induction of apoptosis involves guanosine 3′,5′-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res 60: 3338 – 3342, 2000.en_US
dc.identifier.citedreferenceSoh JW, Mao Y, Kim MG, Pamukcu R, Li H, Piazza GA, Thompson WJ, Weinstein IB. Cyclic GMP mediates apoptosis induced by sulindac derivatives via activation of c-Jun NH2-terminal kinase 1. Clin Cancer Res 6: 4136 – 4141, 2000.en_US
dc.identifier.citedreferenceSoh JW, Mao Y, Liu L, Thompson WJ, Pamukcu R, Weinstein IB. Protein kinase G activates the JNK1 pathway via phosphorylation of MEKK1. J Biol Chem 276: 16406 – 16410, 2001.en_US
dc.identifier.citedreferenceYoon J-T, Palazzo AF, Xiao D, et al. CP248, a derivative of Exisulind, causes growth inhibition, mitotic arrest and abnormalities in microtubule polymerization in glioma cells. Mol Cancer Ther 1: 393 – 404, 2002.en_US
dc.identifier.citedreferenceGoluboff ET, Shabsigh A, Saidi JA, et al. Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis. Urology 53: 440 – 445, 1999.en_US
dc.identifier.citedreferencevan Stolk R, Stoner G, Hayton WL, et al. Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis. Clin Cancer Res 6: 78 – 89, 2000.en_US
dc.identifier.citedreferenceSoriano AF, Helfrich B, Chan DC, Heasley LE, Bunn PA Jr, Chou TC. Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res 59: 6178 – 6184, 1999.en_US
dc.identifier.citedreferenceBanks-Schlegel SP, Quintero J. Growth and differentiation of human esophageal carcinoma cell lines. Cancer Res 46: 250 – 258, 1986.en_US
dc.identifier.citedreferenceJiang W, Zhang YJ, Kahn SM, et al. Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer Proc Natl Acad Sci USA 90: 9026 – 9030, 1993.en_US
dc.identifier.citedreferenceVermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 184: 39 – 51, 1995.en_US
dc.identifier.citedreferenceWestendorf JM, Rao PN, Gerace L. Cloning of cDNAs for M-phase phosphoproteins recognized by the MPM2 monoclonal antibody and determination of the phosphorylated epitope. Proc Natl Acad Sci USA 91: 714 – 718, 1994.en_US
dc.identifier.citedreferenceShirin H, Sordillo EM, Oh SH, Yamamoto H, Delohery T, Weinstein IB, Moss SF. Helicobacter pylori inhibits the G1 to S transition in AGS gastric epithelial cells. Cancer Res 59: 2277 – 2281, 1999.en_US
dc.identifier.citedreferenceLakritz J, Plopper CG, Buckpitt AR. Validated high-performance liquid chromatography-electrochemical method for determination of glutathione and glutathione disulfide in small tissue samples. Anal Biochem 247: 63 – 68, 1997.en_US
dc.identifier.citedreferenceEberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107: 1183 – 1188, 1994.en_US
dc.identifier.citedreferenceRistimaki A, Honkanen N, Jankala H, Sipponen P, Harkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 57: 1276 – 1280, 1997.en_US
dc.identifier.citedreferenceShamma A, Yamamoto H, Doki Y, et al. Up-regulation of cyclooxygenase-2 in squamous carcinogenesis of the esophagus. Clin Cancer Res 6: 1229 – 1238, 2000.en_US
dc.identifier.citedreferenceShirvani VN, Ouatu-Lascar R, Kaur BS, Omary MB, Triadafilopoulos G. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure. Gastroenterology 118: 487 – 496, 2000.en_US
dc.identifier.citedreferenceLiu XH, Rose DP. Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines. Cancer Res 56: 5125 – 5127, 1996.en_US
dc.identifier.citedreferencePinto JT, Rivlin RS. Antiproliferative effects of allium derivatives from garlic. J Nutr 131: 1058S – 1060S, 2001.en_US
dc.identifier.citedreferenceKyriakis JM, Banerjee P, Nikolakaki E, et al. The stress-activated protein kinase subfamily of c-Jun kinases. Nature 369: 156 – 160, 1994.en_US
dc.identifier.citedreferenceChen YR, Wang W, Kong AN, Tan TH. Molecular mechanisms of c-Jun N-terminal kinase-mediated apoptosis induced by anticarcinogenic isothiocyanates. J Biol Chem 273: 1769 – 1775, 1998.en_US
dc.identifier.citedreferencevan Lieshout EM, Tiemessen DM, Peters WH, Jansen JB. Effects of nonsteroidal anti-inflammatory drugs on glutathione S- transferases of the rat digestive tract. Carcinogenesis 18: 485 – 490, 1997.en_US
dc.identifier.citedreferenceShirin H, Pinto JT, Kawabata Y, et al. Antiproliferative effects of S-allylmercaptocysteine on colon cancer cells when tested alone or in combination with sulindac sulfide. Cancer Res 61: 725 – 731, 2001.en_US
dc.identifier.citedreferenceCompton KR, Orringer MB, Beer DG. Induction of glutathione s-transferase-pi in Barrett's metaplasia and Barrett's adenocarcinoma cell lines. Mol Carcinog 24: 128 – 136, 1999.en_US
dc.identifier.citedreferenceSharma RA. Translational medicine: targetting cyclo-oxygenase isozymes to prevent cancer. Q J M 95: 267 – 273, 2002.en_US
dc.identifier.citedreferenceSubbaramaiah K, Zakim D, Weksler BB, Dannenberg AJ. Inhibition of cyclooxygenase: a novel approach to cancer prevention. Proc Soc Exp Biol Med 216: 201 – 210, 1997.en_US
dc.identifier.citedreferenceSteinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342: 1946 – 1952, 2000.en_US
dc.identifier.citedreferenceWilson KT, Fu S, Ramanujam KS, Meltzer SJ. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res 58: 2929 – 2934, 1998.en_US
dc.identifier.citedreferenceSubbaramaiah K, Hart JC, Norton L, Dannenberg AJ. Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2. Evidence for involvement of ERK1/2 AND p38 mitogen- activated protein kinase pathways. J Biol Chem 275: 14838 – 14845, 2000.en_US
dc.identifier.citedreferenceCorasaniti MT, Strongoli MC, Piccirilli S, et al. Apoptosis induced by gp120 in the neocortex of rat involves enhanced expression of cyclooxygenase type 2 and is prevented by NMDA receptor antagonists and by the 21-aminosteroid U-74389G. Biochem Biophys Res Commun 274: 664 – 669, 2000.en_US
dc.identifier.citedreferenceGilroy DW, Colville-Nash PR. New insights into the role of COX 2 in inflammation. J Mol Med 78: 121 – 129, 2000.en_US
dc.identifier.citedreferenceJoldersma M, Klein-Nulend J, Oleksik AM, Heyligers IC, Burger EH. Estrogen enhances mechanical stress-induced prostaglandin production by bone cells from elderly women. Am J Physiol Endocrinol Metab 280: E436 – E442, 2001.en_US
dc.identifier.citedreferenceOgasawara A, Arakawa T, Kaneda T, Takuma T, Sato T, Kaneko H, Kumegawa M, Hakeda Y. Fluid shear stress-induced cyclooxygenase-2 expression is mediated by C/EBP beta, cAMP-response element-binding protein, and AP-1 in osteoblastic MC3T3-E1 cells. J Biol Chem 276: 7048 – 7054, 2001.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.